ArticleJournal of cancer research and clinical oncology2023
Identification an innovative classification and nomogram for predicting the prognosis of thyroid carcinoma patients and providing therapeutic schedules.
Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid carcinoma (THCA) represents a prevalent form of cancer globally, with its incidence demonstrating an upward trend in recent years. Accumulating evidence has indicated that programmed cell death (PCD) patterns exert a vital influence on tumor progression. Nevertheless, the association between PCD and the prognosis of patients with papillary thyroid carcinoma remains to be elucidated. The current study endeavors to examine the link between PCD and the prognosis of thyroid cancer while concurrently developing a prognostic index based on PCD genes. MATERIALS AND
methodsProgrammed cell death patterns were employed to construct the model and define clusters. Gene expression profile genomics and clinical data pertaining to 568 patients with thyroid cancer were sourced from the TCGA database. In addition, single-cell transcriptome data GSE184362 were procured from the Gene Expression Omnibus (GEO) database for subsequent analysis.
resultsThe study harnessed six machine learning algorithms to create a programmed cell death signature (PCDS). Ultimately, the model developed via SVM was chosen as the optimal model, boasting the highest C-index. Moreover, the application of non-negative matrix factorization (NMF) led to the identification of two molecular subtypes of THCA, each characterized by distinct vital biological processes and drug sensitivities. The investigation revealed that PCDS is linked to chemokines, interleukins, interferons, and checkpoint genes, as well as pivotal components of the tumor microenvironment, as determined through a comprehensive analysis of bulk and single-cell transcriptomes. Patients with THCA and elevated PCDS values are more inclined to exhibit resistance to conventional chemotherapy regimens, yet may display heightened responsiveness to targeted therapeutic agents. Finally, we established a nomogram model based on multivariable cox and logistic regression analyses to predict the overall survival of THCA patients.
conclusionThis research sheds new light on the role of programmed cell death (PCD) patterns in THCA. By conducting an in-depth analysis of various cell death patterns, a novel PCD model has been devised, capable of accurately predicting the clinical prognosis and drug sensitivity of patients with THCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.